Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 9:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 3,912 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hypertension Clear all
Recruiting No phase listed Observational Accepts healthy volunteers

Low Energy Availability and Hypertension in Division I HBCU Athletes

NCT07583940
View directory record Official record
Conditions
Vascular Stiffness, Hypertension (HTN), Nutritional Deficiency Related Cardiovascular Risk in Athletes
Interventions
Not listed
Lead sponsor
North Carolina Agriculture & Technical State University
Other
Eligibility
18 Years to 26 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Greensboro, North Carolina
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 31, 2026, 9:32 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

A Comparison of Compliance Between Clonidine Patch and Methyldopa for the Treatment of Chronic Hypertension in Pregnancy

NCT00329511
View directory record Official record
Conditions
Hypertension
Interventions
methyldopa vs. clonidine, clonidine patch
Drug
Lead sponsor
Afshan B. Hameed, M.D.
Other
Eligibility
18 Years to 45 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Jan 30, 2018 · Synced Oct 31, 2026, 9:32 AM EDT
Completed Phase 3 Interventional

Mono vs. Dual Therapy for Pediatric Pulmonary Arterial Hypertension

NCT04039464
View directory record Official record
Conditions
Pediatric Pulmonary Hypertension
Interventions
Mono-Therapy with Sildenafil, Duo-Therapy with Sildenafil + Bosentan
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
3 Months to 18 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
10
States / cities
Aurora, Colorado • St. Petersburg, Florida • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 31, 2026, 9:32 AM EDT
Recruiting Not applicable Interventional

Remote Postpartum Blood Pressure Monitoring and Cardiovascular Education

NCT06920563
View directory record Official record
Conditions
Pre-Eclampsia; Complicating Pregnancy, Gestational Hypertension
Interventions
Video, Text Reminder, Blood pressure threshold
Other
Lead sponsor
Ochsner Health System
Other
Eligibility
18 Years and older · Female only
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Oct 31, 2026, 9:32 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

DASH-Sodium Trial in Adolescents

NCT02993458
View directory record Official record
Conditions
Blood High Pressure
Interventions
DASH diet, Low Na diet, High Na diet, Usual Diet
Other
Lead sponsor
Purdue University
Other
Eligibility
11 Years to 15 Years
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Indianapolis, Indiana • West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 8, 2017 · Synced Oct 31, 2026, 9:32 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate Pharmacokinetics of Tafluprost Ophthalmic Solution (0.0015%) in Pediatric Patients With Glaucoma or Ocular Hypertension

NCT02102750
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Preservative free tafluprost opthalmic solution
Drug
Lead sponsor
Santen Oy
Industry
Eligibility
1 Month to 17 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 10, 2017 · Synced Oct 31, 2026, 9:32 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Continuation of the nuMoM2b Heart Health Study

NCT05472597
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
Not listed
Lead sponsor
RTI International
Other
Eligibility
18 Years and older · Female only
Enrollment
4,048 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
14
States / cities
Orange, California • Newark, Delaware • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 31, 2026, 9:32 AM EDT
Recruiting Phase 3 Interventional

Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)

NCT07218796
View directory record Official record
Conditions
Cataract, Glaucoma, Ocular Hypertension
Interventions
Bimatoprost Implant System, SpyGlass IOL, Timolol Maleate Ophthalmic Solution, 0.5%, Commercial IOL
Drug · Device
Lead sponsor
SpyGlass Pharma, Inc.
Industry
Eligibility
22 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 31, 2026, 9:32 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of T-2345 Compared to Xalatan in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

NCT02059278
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Ocular Hypertension
Interventions
T-2345, Xalatan
Drug
Lead sponsor
Nephron Pharmaceuticals Corporation
Industry
Eligibility
18 Years and older
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Aug 22, 2018 · Synced Oct 31, 2026, 9:32 AM EDT
Completed No phase listed Observational Results available

52-104 Week Off-therapy Second Extension to Study CSPP100A2365

NCT01420068
View directory record Official record
Conditions
Hypertension
Interventions
SPP100
Drug
Lead sponsor
LXO Group
Industry
Eligibility
6 Years to 17 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
11
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Dalton, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Oct 31, 2026, 9:32 AM EDT
Withdrawn Phase 4 Interventional

The Efficacy and Safety of Cleviprex in Ventriculostomy Patients Requiring IV Antihypertensive Therapy

NCT01042574
View directory record Official record
Conditions
Hypertension, Intracranial Hemorrhage, Subarachnoid Hemorrhage
Interventions
Clevidipine butyrate
Drug
Lead sponsor
Methodist Healthcare - Memphis
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Oct 31, 2026, 9:32 AM EDT
Completed No phase listed Observational

International BPA Registry

NCT03245268
View directory record Official record
Conditions
Chronic Thromboembolic Pulmonary Hypertension, CTEPH
Interventions
Balloon pulmonary angioplasty
Procedure
Lead sponsor
International CTEPH Association
Other
Eligibility
Not listed
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
5
States / cities
La Jolla, California • Boston, Massachusetts • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2022 · Synced Oct 31, 2026, 9:32 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Pilot Study of the Safety and Efficacy of Anakinra (Recombinant Human Interleukin-1 Receptor Antagonist) in Pulmonary Hypertension

NCT01479010
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Anakinra 100 mg subcutaneously daily
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 31, 2026, 9:32 AM EDT
Terminated Phase 2 Interventional

PRIMEx - A Study of 2 Doses of Oral CXA-10 in Pulmonary Arterial Hypertension (PAH)

NCT03449524
View directory record Official record
Conditions
PAH
Interventions
75mg CXA-10, 150mg CXA-10, Placebo
Drug · Other
Lead sponsor
Complexa, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Oct 31, 2026, 9:32 AM EDT
Terminated Not applicable Interventional Results available

Pharmacokinetic Study of Milrinone in Babies With Persistent Pulmonary Hypertension of the Newborn

NCT01088997
View directory record Official record
Conditions
Persistent Fetal Circulation Syndrome
Interventions
Milrinone Lactate
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 10 Days
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Detroit, Michigan • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Oct 31, 2026, 9:32 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

PeriOperative ISchemic Evaluation-3 Trial

NCT03505723
View directory record Official record
Conditions
Perioperative Bleeding, Venous Thrombosis, Arterial Thrombosis
Interventions
Tranexamic Acid, Placebo (Saline), Perioperative hypotension-avoidance strategy, Perioperative hypertension-avoidance strategy
Drug · Other
Lead sponsor
Population Health Research Institute
Other
Eligibility
45 Years and older
Enrollment
9,535 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
12
States / cities
New Haven, Connecticut • Weston, Florida • New York, New York + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Oct 31, 2026, 9:32 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Age-Related Changes in Body Composition

NCT01517113
View directory record Official record
Conditions
Hypertension, Atherosclerosis
Interventions
Not listed
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
50 Years to 90 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 31, 2026, 9:32 AM EDT
Terminated Phase 3 Interventional

Hypertonic Saline vs. Mannitol for Elevated Intercranial Pressure

NCT01111682
View directory record Official record
Conditions
Traumatic Brain Injury, Elevated Intracranial Pressure
Interventions
Mannitol, Hypertonic Saline
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 5, 2013 · Synced Oct 31, 2026, 9:32 AM EDT
Recruiting Phase 2 Interventional

Pulmonary Hypertension SOLAR

NCT04778046
View directory record Official record
Conditions
Interstitial Lung Disease, COPD, Pulmonary Arterial Hypertension
Interventions
Hyperpolarized 129Xe
Drug
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 31, 2026, 9:32 AM EDT
Completed Phase 1 Interventional

Pravastatin for Prevention of Preeclampsia

NCT01717586
View directory record Official record
Conditions
Preeclampsia
Interventions
Pravastatin, Placebo
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years and older · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
3
States / cities
Chicago, Illinois • Pittsburgh, Pennsylvania • Galveston, Texas
Source: ClinicalTrials.gov public record
Updated May 4, 2025 · Synced Oct 31, 2026, 9:32 AM EDT
Completed No phase listed Observational Results available

PRESERFLO® MicroShunt Extension Study

NCT04333433
View directory record Official record
Conditions
Primary Open-angle Glaucoma
Interventions
PRESERFLO® MicroShunt, Trabeculectomy
Device · Procedure
Lead sponsor
InnFocus Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
279 participants
Timeline
2020 – 2022
U.S. locations
19
States / cities
Glendale, Arizona • Fayetteville, Arkansas • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2024 · Synced Oct 31, 2026, 9:32 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Age on Latanoprost 0.005% in Patients With Glaucoma

NCT00224289
View directory record Official record
Conditions
Glaucoma
Interventions
Latanoprost 0.005%
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 10, 2012 · Synced Oct 31, 2026, 9:32 AM EDT
Completed Phase 2 Interventional

Next Generation Rocklatan

NCT06441643
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
AR-17043 Ophthalmic Solution, PG043 Ophthalmic Solution, Latanoprost 0.005% Ophthalmic Solution, Netarsudil 0.02% Ophthalmic Solution, Netarsudil 0.02%/Latanoprost 0.005% Ophthalmic Solution, AR-17043 Vehicle
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
12
States / cities
Garden Grove, California • Inglewood, California • Newport Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 31, 2026, 9:32 AM EDT
Terminated Not applicable Interventional

B'More for a Peaceful Motherhood Hypertension Control Study

NCT03741608
View directory record Official record
Conditions
Hypertension
Interventions
High blood pressure management education, Home blood pressure measurement
Behavioral
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced Oct 31, 2026, 9:32 AM EDT